Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.